This Notice of Funding Opportunity (NOFO) aims toprovide a proof-of-principle for a novel strategy for Alzheimer Disease and Alzheimer Related Dementias (AD/ADRD) immunotherapies.
Specifically, the goal is to examine if a novel immunotherapeutic approach in cancer immunotherapy with Chimeric Antigen
Receptor (CAR) immune cellscould be customized as treatments for AD/ADRD.
This NOFO utilizes the R61/R33Exploratory/Developmental Phased Award activity code.
The R61 phase provides up to 2 years of support for initial developmental activities.
The R33 phase provides up to 3 years of support for expanded activities.